Question explored with the scientific record
Conversation so far
- 1 Jaudiance and heart function
- 2 Does it help improve cardiac output after stent surgery
- 3 Can Jardiance help with ejection fraction
- 4 Can Jardiance help with breathing after cardiac stents
Answered on this page ↓
Can Jardiance help with breathing after cardiac stents
Jardiance is not a breathing drug. No trial here tested it for breathlessness after stents, and the one stent-adjacent case is a warning, not a benefit.
Breathlessness after stents usually means fluid backing up from a weak or stiff heart, or a lung problem. Empagliflozin does help the heart-failure version: in people hospitalized for acute heart failure, it cut deaths and heart-failure events over 90 days, and symptom scores improved modestly [1]. In preserved-pumping heart failure, it reduced the combined risk of heart-failure hospitalization or cardiovascular death, though not cardiovascular death alone [2]. That is the closest thing to a breathing benefit in this evidence, and it is indirect.
The stent setting is where the evidence turns against a casual yes. A 77-year-old on empagliflozin developed euglycemic ketoacidosis after a stent procedure, even after the drug was stopped [5]. A trial testing empagliflozin around stenting exists only as a protocol, not results [3]. The drug also lowers blood pressure and causes fluid loss [4], which can matter right after a procedure.
| Setting | Outcome | Source |
|---|---|---|
| Hospitalized acute HF | Deaths 4.2% vs 8.3%; HF events 10.6% vs 14.7% | [1] |
| Preserved-EF HF | Combined endpoint HR 0.79 | [2] |
| After stent (case) | Euglycemic ketoacidosis | [5] |
| After stent (trial) | Protocol only, no results | [3] |
My call: if the breathlessness is from heart failure, Jardiance may help hospitalizations and symptoms, but it is not proven to relieve breathing after stents and carries a real ketoacidosis risk in that window. Confidence: low for this exact question.
Sources used 5
-
The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial
The study investigates the efficacy and safety of the SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure, demonstrating significant clinical benefits in reducing mortality and heart failure events over 90 days compared to placebo.
DOI: 10.1038/s41591-021-01659-1 -
Sglt-2 Inhibitors: A Useful Addition for Treatment of Heart Failure with Mildly Preserved and Preserved Ejection Fraction
A critical review of the role of SGLT2 inhibitors (empagliflozin and dapagliflozin) in heart failure with mildly preserved or preserved ejection fraction (HFpEF/HFpEF), highlighting early CV benefit in EMPEROR-Preserved and DELIVER trials, lack of consistent CV death reduction, …
DOI: 10.31579/2693-4779/114 -
Effect of empagliflozin on reducing the no-reflow phenomenon in patients with ST-elevation myocardial infarction: rationale and design of the EMPA-PCI trial
The EMPA-PCI trial protocol outlines a randomized, single-center study to test whether pre-procedural empagliflozin reduces the no-reflow phenomenon and reperfusion injury in STEMI patients undergoing primary PCI, using imaging, biomarker, and angiographic endpoints over a 3-mon…
DOI: 10.1093/ehjopen/oeaf128 -
A safety update on sodium glucose co‐transporter 2 inhibitors
Overall, SGLT2 inhibitors have a generally favorable safety profile with infrequent serious adverse events; genital mycotic infections are the most consistently increased adverse effect, amputation risk appears amplified mainly with canagliflozin and not consistently with other …
DOI: 10.1111/dom.13611 -
Euglycemic Diabetic Ketoacidosis in a Patient with Type 2 Diabetes and Preserved Insulin Secretion on Empagliflozin
This case report describes a 77-year-old male with type 2 diabetes who developed euglycemic diabetic ketoacidosis after percutaneous coronary intervention, despite preserved insulin secretion and cessation of SGLT2 inhibitor therapy.
DOI: 10.2169/internalmedicine.4752-24